Introduction• Literature review‐Molecular biology of EGFR mutations‐Clinical characteristics
of NSCLC patients with EGFR mutations‐Genetic characteristics of EGFR‐mutated tumours …

Introduction We conducted a systematic review and meta-analysis to assess epidermal
growth factor receptor (EGFR) gene copy number as a potential biomarker of survival for …

Patients with non‐small‐cell lung cancer (NSCLC) appear to gain particular benefit from
treatment with epidermal growth factor receptor (EGFR) tyrosine‐kinase inhibitors (TKI) if …

In recent years, a number of new agents that target specific molecular pathways in non-small
cell lung cancer (NSCLC) have been investigated. Much effort has been focused on …

In non-small cell lung cancer (NSCLC) patients, somatic EGFR and K-ras mutations predict
therapeutic effectiveness and resistance, respectively, to EGFR tyrosine kinase inhibitors …

5,262,564 A 11/1993 Kun et al. In one aspect, the present invention provides a method of
5.283. 352 A 2f1994 Bäckström et all 532,140 A 6, 1994 Comi 1 treating breast cancer that is …

Background: Therapy by tyrosine kinase inhibitors (TKI) has become inevitable in treatment
of advanced NSCLC. Mutations in EGFR and KRAS genes have been identified as the main …

Epidermal growth factor receptor (EGFR) gene copy number has been proposed as a
candidate biomarker for predicting treatment response to EGFR tyrosine kinase inhibitors …

As 20% of stage I NSCLC patients develop recurrent and often incurable cancer, the
identification of prognostic markers has a meaningful clinical application. The biological …

Introduction: The epidermal growth factor receptor (EGFR) and its family members are
involved in many aspects of tumor biological processes. Aberrant activation of the EGFR …